Lung Injury Induced by Crizotinib and Entrectinib in a Patient with <i>ROS1</i>-rearranged Non-small-cell Lung Cancer
Author:
Affiliation:
1. Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan
Publisher
Japanese Society of Internal Medicine
Subject
General Medicine,Internal Medicine
Link
https://www.jstage.jst.go.jp/article/internalmedicine/62/23/62_1255-22/_pdf
Reference12 articles.
1. 1. Tanimura M, Kataoka N, Kunimatsu Y, et al. Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: a case report. Respirol Case Rep 9: e0857, 2021.
2. 2. Hwang HJ, Kim MY, Choi CM, Lee JC. Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: clinical and radiologic characteristics and risk factors. Medicine 98: 48, 2019.
3. 3. Yoneda KY, Scranton JR, Cadogan MA, et al. Interstitial lung disease associated with crizotinib in patients with advanced non- small cell lung cancer: independent review of four PROFILE trials. Clin Lung Cancer 18: 472-479, 2017.
4. 4. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371: 1963-1971, 2014.
5. 5. Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36: 1405-1411, 2018.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Crizotinib/Entrectinib;Reactions Weekly;2024-04-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3